As reported by Money News, Cipla Ltd., India’s fifth-largest drugmaker by sales, plans to reduce investment in biosimilars to sharpen its focus on building a portfolio of high-margin respiratory products. Cipla’s original plan to build a biotech plant in South Africa has been put on hold. Cipla’s CEO, Umang Vohra, states that while “they are not moving away from biosimilars, . . . [they] are not in the aim to make them at $1 a day.” Money News states that Cipla has been among the hardest hit in the past year from government-imposed price caps and expects further disruptions from a nationwide tax reform plan.
